Remission of diabetes with glutamic acid decarboxylase antibody positivity that developed after the administration of olanzapine: a case report

Read full text Summarise with VIRAT
Authors: Kyuho Kim, Soo Hyun Seo, Yun Ji Hong, Woojae Myung, Bomi Kim, Chang Ho Ahn, Sung Hee Choi, Hak Chul Jang, Tae Jung Oh
Cited by: 0
References: 17

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

Olanzapine is a second-generation antipsychotic drug associated with the development of type 2 diabetes. However, the development and remission of diabetes with glutamic acid decarboxylase (GAD) antibody (Ab) positivity related to olanzapine treatment have not been reported. Here, we present the case of a 33-year-old man taking olanzapine who was diagnosed with diabetes with GAD Ab positivity complicated by diabetic ketoacidosis (DKA). After discontinuation of the drug and tight glycemic control, his diabetes remitted, and the GAD Ab became negative spontaneously after 18 months. The classification of diabetes is challenging because of overlapping autoimmune and metabolic features. Olanzapine may have contributed to pancreatic β-cell apoptosis, which could potentially trigger autoimmunity and the development of type 1 diabetes-like features (DKA as the initial presentation, a low C-peptide level, and GAD Ab positivity). The rapid amelioration of hyperglycemia and weight reduction may be responsible for the remission of diabetes after the discontinuation of olanzapine.

Fields of Study & Subjects

Diabetes and associated disorders Autoimmune Neurological Disorders and Treatments Diabetes Management and Research

Publication details

Journal / source
Precision and Future Medicine
Volume
10
Issue
1
Pages
51–56
Publication date
31 March 2026
Language
EN